Associations between legal performance-enhancing substance use and future cardiovascular disease risk factors in young adults: A prospective cohort study
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Legal performance-enhancing substances (PES), such as creatine, are commonly used by adolescents and young adults. As PES are mostly unregulated by the US Food and Drug Administration, there has been limited empirical attention devoted to examining their long-term safety and health outcomes. Preliminary studies have demonstrated associations between PES use and severe medical events, including hospitalizations and death. PES could be linked to cardiovascular disease (CVD), the most common cause of mortality in the US, by altering the myocardium, vasculature, or metabolism. The objective of this study was to examine prospective associations between the use of legal PES in young adulthood and CVD risk factors at seven-year follow-up. MATERIALS AND METHODS: Nationally representative longitudinal cohort data from the National Longitudinal Study of Adolescent to Adult Health, Waves III (2001-2002) and IV (2008), were analyzed. Regression models determined the prospective association between the use of legal PES (e.g. creatine monohydrate) and CVD risk factors (e.g. body mass index, diabetes, hypertension, hyperlipidemia), adjusting for relevant covariates. RESULTS: Among the diverse sample of 11,996 male and female participants, no significant differences by PES use in body mass index, diabetes, hypertension, or hyperlipidemia were noted at Wave III. In unadjusted comparisons, legal PES users (versus non-users) were more likely to be White, be male, be college educated, drink alcohol, and engage in weightlifting, exercise, individual sports, team sports, and other strength training. There were no significant prospective associations between legal PES use at Wave III and body mass index, hemoglobin A1c, systolic and diastolic blood pressure, and cholesterol (total, HDL, LDL, triglycerides) deciles at seven-year follow-up (Wave IV), adjusting for demographics, health behaviors, and Wave III CVD risk factors. Similarly, there were no significant prospective associations between legal PES use and diabetes, hypertension, or hyperlipidemia based on objective measures or self-reported medications and diagnoses, adjusting for demographics, health behaviors, and Wave III CVD risk. CONCLUSIONS: We do not find evidence for a prospective association between legal PES use and CVD risk factors in young adults over seven years of follow-up, including BMI, diabetes, hypertension, or hyperlipidemia. It should be noted that legal PES use was operationalized dichotomously and as one broad category, which did not account for frequency, amount, or duration of use. Given the lack of regulation and clinical trials data, observational studies can provide much needed data to inform the safety and long-term health associations of legal PES use and, in turn, inform clinical guidance and policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Study populations were heterogeneous and included youth athletes participating in organized football programs, adolescent females with selective serotonin reuptake inhibitor (SSRI)-resistant major depressive disorder, and patients with pediatric inflammatory myopathies, including juvenile dermatomyositis [12-16].”
From Evaluating the Safety of Creatine Monohydrate in Adolescents: A Systematic Review of Renal, Hepatic, and Cardiometabolic Outcomes (2026) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prospective cohort study assessed long-term cardiometabolic outcomes over approximately seven years following initiation of creatine-containing performance-enhancing supplements during adolescence [15].”
From Evaluating the Safety of Creatine Monohydrate in Adolescents: A Systematic Review of Renal, Hepatic, and Cardiometabolic Outcomes (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across all included studies, creatine monohydrate supplementation was described as well-tolerated, with no serious adverse events attributed to supplementation [12-15].”
From Evaluating the Safety of Creatine Monohydrate in Adolescents: A Systematic Review of Renal, Hepatic, and Cardiometabolic Outcomes (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These outcomes included body mass index, blood pressure, glycemic markers, lipid profiles, and the incidence of diabetes, hypertension, or hyperlipidemia [15].”
From Evaluating the Safety of Creatine Monohydrate in Adolescents: A Systematic Review of Renal, Hepatic, and Cardiometabolic Outcomes (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, across the five included studies, creatine monohydrate supplementation in pediatric, adolescent, and young adult populations was not associated with clinically meaningful renal, hepatic, hematologic, or cardiometabolic safety concerns during the reported follow-up periods [12-16].”
From Evaluating the Safety of Creatine Monohydrate in Adolescents: A Systematic Review of Renal, Hepatic, and Cardiometabolic Outcomes (2026) · cites this paper as [15]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · cited 1×
“, diabetes, hypertension, dyslipidemia) commonly develop in young adulthood when legal PES use is prevalent, and CVD remains the leading cause of death in the US [12, 13].”
BackgroundWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Journal of The American College of Cardiology
(2015) · Wilderness & Environmental Medicine · doi:10.1016/j.wem.2015.03.023 · Cited by 2,584
Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 1,057 · cited 2×
“However, creatine use also has been linked to weight gain [23], which could represent a detriment to long-term cardiovascular health, as higher weight and BMI are primary risk factors for CVD [24].”
Background(1973) · New England Journal of Medicine · doi:10.1056/nejm197307122890231 · Cited by 895
The enigma of male eating disorders: A critical review and synthesis
Murray, S. B., Nagata, J. M., Griffiths, S., Calzo, J. P., Brown, T. A., Mitchison, D., Blashill, A. J., & Mond, J. M. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.08.001 · Cited by 702
Self-citationPope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1058 · Cited by 658 · cited 2×
“In the present study, we focus on CVD risk factors– including diabetes, hypertension, abnormal lipid profiles, and obesity–in young adulthood given that these outcomes may take many years to fully manifest [38, 42] and evidence suggesting that use of illegal PES (e.”
BackgroundPope, H. G., Kouri, E. M., & Hudson, J. I. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.2.133 · Cited by 556
Cited by
Deer, L. K., Chen, S., Thwaites, N. A., Davis, E. P., & Doom, J. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111474 · Cited by 14
ANÁLISE DOS EFEITOS CARDIOVASCULARES DO USO CONTÍNUO DE CREATINA: UMA REVISÃO SISTEMÁTICA
Silva, A., Correia, M. A. B. D. M., & Fé, L. M. F. B. M. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i11.5870 · Cited by 3
Medical Complications of Eating Disorders in Boys and Men
Nagata, J. M., Ganson, K. T., & Golden, N. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-67127-3_9 · Cited by 1
Self-citationRubinchuk, A., Dulkoski, Z., Persaud, N. A., & Wallen, M. (2026) · Cureus · doi:10.7759/cureus.106808
“After adjustment for demographic characteristics, health behaviors, and baseline cardiometabolic risk factors, no significant associations were identified between legal performance-enhancing substance use, including creatine-containing supplements, and adverse cardiometabolic outcomes [15].”
InfluentialCoronary Artery Disease in Male Athletes—Is Sport Healthy in the Long Run?
Kampka, Z., & Wybraniec, M. T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145329
“The influence of legal performance-enhancing substances such as androgen prohormones, caffeine and creatine on CV health requires further examination due to mixed findings in research studies [53].”
Metadata
- Authors
- Nagata, J. M., Ganson, K. T., Cunningham, M. L., Mitchison, D., Lavender, J. M., Blashill, A. J., Gooding, H. C., & Murray, S. B.
- Affiliations
- University of California, San Francisco (US)
- University of Toronto (CA)
- The University of Sydney (AU)
- Western Sydney University (AU)
- Uniformed Services University of the Health Sciences (US)
- San Diego State University (US)
- Emory University (US)
- University of Southern California (US)
- Corresponding author
- Nagata, Jason M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-12-15
- Volume
- 15
- Issue
- 12
- Pages
- e0244018
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7737961
- OpenAlex
- W3111677383
- Cited by
- 5
- References
- 58
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1 · 2021: 1
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pediatric Scientist Development Program (K12HD000850-33)
- American Heart Association (CDA34760281)
- National Institutes of Health (MH115184)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01-HD31921)
- Topics
- Social Sciences › Sociology and Political Science › Doping in Sports
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Pharmacological Effects and Assays
- Keywords
- creatine monohydrate, cardiovascular risk factors, young adults, body mass index, diabetes mellitus, hypertension, hyperlipidemia, long-term health effects, Add Health, resistance training, dietary supplements, supplement safety, health behavior, alcohol consumption, exercise participation, sex differences, racial differences, socioeconomic status
- MeSH terms
- Adolescent, Adult, Blood Pressure, Cardiovascular Diseases, Cholesterol, Creatine, Drug Utilization, Female, Hemoglobin A, Humans, Life Style, Male, Exercise, Performance-Enhancing Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.